CEP 751

Drug Profile

CEP 751

Alternative Names: CEP-751

Latest Information Update: 09 Apr 2010

Price : $50

At a glance

  • Originator Cephalon
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 31 Dec 2001 Schwarz Pharma has terminated its licence for CEP 751
  • 13 Jan 2000 Schwarz Pharma has licensed Cephalon's tyrosine kinase receptor compounds
  • 06 Aug 1999 Two preclinical studies have been added to the pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top